More: EULAR 2008: The European League Against Rheumatism Annual Congress

EULAR 2008: New Options With Biologics for RA: Recent Advances With Novel Therapeutic Agents CME/CE

June 11 - 14, 2008, Paris, France

Author Information and Disclosures

This activity is not sanctioned by, nor a part of, the European League Against Rheumatism. Conference news does not receive grant support and is produced independently.

Release Date: June 27, 2008Valid for credit through June 27, 2009

Credits Available
Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s) for physicians;
Nurses - 0.5 nursing contact hours (0.25 contact hours are in the area of pharmacology)

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME/CE Activity

Legal Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the European League Against Rheumatism. These materials and the related activity are not sanctioned by the European League Against Rheumatism or the commercial supporter of the conference and do not constitute an official part of that conference.

Copyright © 2008 Medscape.


Roche

Learning Objectives
Upon completion of this activity, participants will be able to:
  1. Discuss the systemic manifestations associated with rheumatoid arthritis (RA)
  2. Evaluate current treatments and their limitations as they relate to the management of RA disease and its systemic manifestations
  3. Discuss advances in treatment options and their contribution to managing comorbidity and achieving a holistic approach to treating patients with RA
Authors and Disclosures

Arthur Kavanaugh, MD
Disclosure: Arthur Kavanaugh, MD, has disclosed that he has received grants for clinical research from Bristol-Myers Squibb, Genentech, Abbott Pharmaceuticals, Amgen, and Centocor.


Vibeke Strand, MD, FACP
Disclosure: Vibeke Strand, MD, FACP, has disclosed that she has served as a consultant for Abbott Immunology, Allergan, Almirall, Amgen Corporation, AstraZeneca, Bayhill, Bexel, Biogen Idec, CanFite, Centocor, Chelsea, Cypress Bioscience, Inc., Dainippon Sumitomo, FibroGen, Forest Laboratories, Genelabs, Genentech, Human Genome Sciences, Incyte, Jazz Pharmaceuticals, Lexicon Genetics, Lux Biosciences, Novartis Pharmaceuticals, Novo Nordisk, NOXXON Pharma, Ono Pharmaceuticals, Pfizer, Procter & Gamble, Proprius, Rigel, Roche, sanofi-aventis, Schering-Plough, Serono, SKK, UCB, VLST, Wyeth-Ayerst, XDx, and Zelos Therapeutics. Dr. Strand has also disclosed that she has served on the advisory board for Abbott, Amgen, Biogen Idec, Bristol-Myers Squibb, CanFite, Centocor, Chelsea, Novartis, Pfizer, Roche, Schering-Plough, and UCB. Dr. Strand has also disclosed that she has served on the speaker's bureau for Abbott, Amgen, Centocor, and Pfizer.


Joseph A. Markenson, MD
Disclosure: Joseph A. Markenson, MD, has disclosed that he has received grants for educational activities from Amgen/Wyeth, Abbott, and Bristol-Myers Squibb. Dr. Markenson has also disclosed that he has served as an advisor or consultant to Amgen/Wyeth and Abbott.


Helen Fosam, PhD
Disclosure: Helen Fosam, PhD, has disclosed no relevant financial relationships.


Jayashree Gokhale, PhD
Disclosure: Jayashree Gokhale, PhD, has disclosed no relevant financial relationships.


 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

 
This Activity is sponsored by Medscape Continuing Education Provider Unit.

Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

Provider Number: 6FDKKC-PRV-05

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.